Strides Shasun receives USFDA approval for Efavirenz Tablet

14 Mar 2018 Evaluate

Strides Shasun’s wholly owned subsidiary - Strides Pharma Global has received approval for Efavirenz Tablets USP, 600 mg from the United States Food & Drug Administration (USFDA). Efavirenz Tablet is generic version of Sustiva Tablets of Bristol-Myers Squibb Company.

According to IQVIA data, the US market for Efavirenz Tablets USP, 600 mg is approximately $115 million and Strides is only the second generic company to get the approval for the product under the para IV route. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. The company will be launching the product immediately.

Strides Shasun is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The company has 74 cumulative ANDA filings with USFDA of which 44 ANDAs have been approved as of date and 30 are pending approval.


Strides Pharma Scien Share Price

900.65 -39.00 (-4.15%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×